Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,007,065

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 6:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?

Gilead (GILD) is having a good run despite the volatility on a string of positive updates.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session.

The Zacks Analyst Blog Highlights Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management

Union Pacific, AT&T, Blackstone, Gilead Sciences and Waste Management are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Union Pacific, AT&T & Blackstone

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific Corporation (UNP), AT&T Inc. (T) and Blackstone Inc. (BX).

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Gilead Sciences (GILD) Stock Moves -1.67%: What You Should Know

Gilead Sciences (GILD) closed at $63.50 in the latest trading session, marking a -1.67% move from the prior day.

Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose

Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir

Gilead (GILD) Drugs Get Positive CHMP Opinion for Label Expansion

Gilead's (GILD) COVID-19 treatment Veklury and CAR T-cell therapy Yescarta get positive CHMP recommendation for additional indications.

WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19

Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.

Gilead Sciences (GILD) Stock Moves -0.28%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $65, marking a -0.28% move from the previous day.

Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players

Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.

Company News for Sep 13, 2022

Companies in The News Are: AAPL, BMY, TWTR, GILD

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Should First Trust Large Cap Core AlphaDEX ETF (FEX) Be on Your Investing Radar?

Style Box ETF report for FEX

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $65.28, marking a +0.28% move from the previous day.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $65.10, moving +0.48% from the previous trading session.

Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival

Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.

Halozyme Therapeutics (HALO) Down 10.6% Since Last Earnings Report: Can It Rebound?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?

Smart Beta ETF report for FEX

Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication

The European Commission approves Gilead's (GILD) CAR T-cell therapy, Tecartus, for treating adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.